Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

169.90USD
3:21pm EDT
Change (% chg)

$1.47 (+0.87%)
Prev Close
$168.43
Open
$168.00
Day's High
$170.79
Day's Low
$167.00
Volume
76,543
Avg. Vol
192,083
52-wk High
$195.97
52-wk Low
$59.59

Select another date:

Thu, May 3 2018

BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68

* SAGE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON PIPELINE AND PROGRESS TOWARD LAUNCH READINESS

BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75

* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE

BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share

* PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $164.00 PER SHARE​ Source text for Eikon: Further company coverage:

BRIEF-Sage Therapeutics Announces Proposed Public Offering Of Common Stock

* SAGE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217

* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study

* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS

Select another date: